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To investigate the relationship between survival in colorectal cancer patients and the number of lymph nodes examined by a
pathologist, previously attributed to stage migration, we used data from a cohort of 5174 colorectal cancer patients recruited
between September 1991 and August 1994, and followed-up for 5 years. We selected cases with data present on all prognostic
variables, and stratified them into three groups by number of nodes examined. We made a multivariate survival comparison using a
Cox regression model. In all, there were 3592 cases with data present on all prognostic variables. Patients who had 410 nodes
identified had a significant survival advantage over those who had 5–10 identified, who had in turn a similar advantage over those
with 0–4 identified (Po0.001). This effect was present in the whole group and at all Dukes’ stages, although statistically significant
only in stages B (P¼0.004) and C (P¼0.019). The effect remained after adjustment in a Cox regression model in which the mean
number of nodes taken out by each surgical firm did not predict survival. In a sub-group with data on lymphocytic infiltration into the
primary tumour a survival advantage was noted in those with prominent rather than mild infiltration (Po0.001): the former also
tended to have more nodes found (P¼0.015). Stage migration alone cannot explain these results, as survival advantages are noted
across the whole population independent of stage. Lymphocytic infiltration into the primary tumour is prognostically important, and is
associated with the number of nodes found. Reactive enlargement of lymph nodes in the mesentery may make them easier to find,
reflect immune response to the tumour, and thus indirectly impact upon survival.
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Colorectal cancer is a common malignancy in the western world,
second in frequency only to lung cancer when figures for males
and females are combined (Schottenfeld and Winawer, 1996).
There are around 30000 incident cases in the UK every year, and
more than 150000 in the USA. Surgery remains the primary
treatment in the majority of patients but about half those who
undergo surgery develop incurable recurrent disease. Survival
from colorectal cancer depends upon the tumour stage at
presentation and most patients are in Dukes stage B or C (UICC
stages II and III) at diagnosis (Williams et al, 1995).
Several groups have observed a relationship between the
number of lymph nodes identified at pathological examination
and survival in colorectal cancer patients, examining usually
Dukes’ B, or Dukes’ B and C patients (Michiels et al, 1994; Caplin
et al, 1998; Tepper et al, 2001; Cserni et al, 2002; Goldstein, 2002;
Prandi et al, 2002; Swanson et al, 2003; Jestin et al, 2005). All
groups have concluded that the observed improvement in survival
was an artefact brought about by inadequate laboratory technique:
that is, had more nodes been examined, some of those staged as
Dukes’ B would have been found to be Dukes’ C patients, with
consequently poorer survival. Another study demonstrated that
the proportion of nodes identified as positive increased along with
the number examined, but did not examine survival (Maurel et al,
1998). In this paper, we examine evidence to support the
hypothesis that the effect of number of nodes harvested on
survival is explained by stage migration, using prospective data
from a large UK population based cohort of colorectal cancer
patients.
METHODS
This study was carried out in the former Wessex health region of
South West England. When data collection began in 1991, Wessex
Received 23 May 2006; revised 31 July 2006; accepted 1 August 2006;
published online 12 September 2006
*Correspondence: Dr S George; E-mail: pluto@soton.ac.uk
British Journal of Cancer (2006) 95, 841–847
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
shad a population of just over 3 million. It has a substantial rural
population and a socio-economic profile that is slightly more
affluent than the UK average.
All patients with a new diagnosis of colorectal cancer were
prospectively recorded between September 1991 and August
1994. Staff based in hospitals around the region followed
standard protocols to extract data from medical records and the
data collection identified 5176 cases of colorectal cancer. Data
were checked against routine cancer registry records to ensure
completeness, and included patients referred out of the region
for treatment, patients who had not received any treatment
and cases identified from the death certificate only. Patients
who were treated in Wessex but were not residents were excluded
from the study. Information including details of presentation,
diagnosis, staging and management was recorded and patients
were followed-up for 5 years to determine local recurrence and
survival.
We analysed 5-year all-cause survival data for all patients staged
as Dukes A, B, or C, or ‘D’, but excluded from analysis those where
individual data items were not available: principally, these were
stage data and data on number of nodes removed. The group was
stratified into those with 0–4 nodes identified, those with 5–10
identified, and those with 410 identified. We made univariate
survival comparisons using Kaplan–Meier curves and the log rank
test for all cases combined and for each stage group.
Cox regression was used to estimate the effect of lymph
node count on survival adjusted for possible confounders. These
were identified a priori from previous studies and from
biological inference (Rothman, 1986). Those considered were age
group (o65 years; 65–74; 75–84; 85þ), Dukes’ stage, site of
tumour (right, up to and including splenic flexure, left, and
rectal), histological subtype (classified as adenocarcinoma or
‘other’) and receipt of postoperative chemotherapy. In
addition, the effect of different surgical expertise was entered into
the model by using the proxy measure of average number of nodes
removed by surgical firm. The linear effect of continuous variables
was tested by including quadratic terms in the regression models.
The assumption of proportional hazards was tested using
Schoenfeld residuals. Interaction was tested using likelihood ratio
tests.
For a sample of our population, we had data on degree of
lymphocytic infiltration of the primary tumour as reported by the
examining pathologist: infiltration is reported as being either
‘mild’ or ‘prominent’. Further analysis was undertaken on this
sample including a comparison of survival by number of nodes
identified and a comparison of survival by degree of lymphocytic
infiltration. The mean and median numbers of nodes identified in
the mild and prominent lymphocytic infiltration groups were
compared and the significance of the difference tested using a
Mann–Whitney U test.
Table 1 Number (%) of study participants according to age group, gender, presentation, tumour site, tumour histology, number of lymph nodes identified
and whether or not postoperative chemotherapy was received, by Dukes’ stage group
Dukes’ stage
ABC DA l l
Age group
o65 118 (29) 344 (24) 269 (28) 231 (30) 962 (27)
65–74 158 (39) 483 (33) 311 (33) 270 (35) 1222 (34)
75–84 97 (24) 489 (34) 293 (31) 214 (28) 1093 (30)
85+ 30 (7) 142 (10) 80 (8) 63 (8) 315 (9)
Gender
Male (%) 216/403 (54) 736/1458 (51) 494/953 (52) 408/778 (52) 1854/3592 (52)
Presentation
Elective 390 (97) 1255 (86) 830 (87) 649 (83) 3124 (87)
Emergency 10 (2) 193 (13) 116 (12)) 122 (16) 441 (12)
Incidental 1 (0.2) 5 (0.3) 4 (0.4) 4 (0.5) 14 (0.4)
Not known 2 (0.5) 4 (0.3) 3 (0.3) 3 (0.4) 12 (0.3)
Tumour site
Right colon 55 (14) 529 (36) 290 (30) 305 (39) 1179 (33)
Left colon 162 (40) 558 (38) 344 (36) 289 (37) 1353 (38)
Rectum 186 (46) 371 (25) 319 (34) 184 (24) 1060 (30)
Histology
AdenoCa 374 (93) 1314 (90) 856 (90) 681 (86) 3225 (90)
Other 29 (7) 144 (10) 97 (10) 87 (13) 367 (190)
Number of lymph nodes identified
0–4 149 (37) 390 (27) 286 (30) 279 (36) 1104 (31)
5–10 187 (46) 694 (48) 469 (49) 367 (47) 1717 (48)
410 67 (17) 374 (26) 198 (21) 132 (17) 771 (21)
Postoperative chemotherapy
Received 6 (2) 53 (4) 119 (12) 133 (17) 311 (9)
Not received 397 (99) 1405 (96) 834 (88) 645 (83) 3281 (91)
Total 403 (11) 1458 (41) 953 (27) 778 (22) 3592 (100)
Percentages may not add up to 100% because of rounding.
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sRESULTS
Of the 5176 cases in the original data set two were found to be anal
cancers that had been wrongly included. Of the remaining 5174,
688 had no stage data, and 1398 had no data on number of nodes
examined. Together, these cases accounted for 1473 cases excluded
from analysis. Further cases were excluded because of missing data
on possible confounders, including age, site of tumour, histological
type and receipt of chemotherapy, or because they had zero
survival or apparent negative survival. Following exclusions, 3592
cases remained in our data set, 403 staged as Dukes’ A, 1458
Dukes’ B, 953 Dukes’ C and 778 Dukes’ ‘D’. Table 1 gives the
number (%) of study participants according to age group, gender,
presentation, tumour site, tumour histology, number of lymph
nodes identified and whether or not postoperative chemotherapy
was received, by Dukes’ stage group. The proportion of tumours
identified as adenocarcinomas is lower than expected, implying a
small degree of coding error. However, a significant survival
advantage is still present for the adenocarcinoma group compared
to those described as ‘other’ (P¼0.007).
Figure 1 shows Kaplan–Meier curves for all four Dukes’ stages
and for those with unknown stage. The pattern shows survival
decreasing as Dukes’ stage moves from A to D, with the worst
survival in those with unknown stage. This confirms our anecdotal
observation that, in the UK at least, formal staging is often omitted
in patients presenting with very advanced disease.
Figure 2 shows Kaplan–Meier curves for the three lymph node
groups and for those with unknown number of nodes. Again,
survival in this last group is associated with very poor survival.
The associated log rank statistic is calculated on those groups
where data on number of nodes is known. There is a significant
survival advantage associated with a larger number of nodes
identified across the whole population studied (log rank¼35.05,
df¼2, Po0.001).
The assumption of proportional hazards between lymph node
count groups was not violated (patients classified as: Dukes’ A
P¼0.145; Dukes’ B P¼0.656; Dukes’ C P¼0.309; Dukes’ D
P¼0.516). There was no evidence of interaction between lymph
node count group and treatment by chemotherapy (patients
classified as Dukes’ A P¼0.150; Dukes’ B P¼0.816; Dukes’ C
P¼0.746; Dukes’ D P¼0.123). Neither was there evidence of
significant interaction between lymph node count group and age
group (P¼0.552), Dukes’ stage (P¼0.905) nor histological
tumour type (P¼0.325).
Figures 3–6 show Kaplan–Meier curves and associated log rank
statistics for Dukes A, B, C and D groups, respectively. Within each
group a survival advantage is associated with higher numbers of
nodes identified, although these differences only achieve statistical
significance in the groups containing the largest numbers of cases,
Dukes B (P¼0.004) and Dukes’ C (P¼0.019).
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Figure 1 Five-year survival, 5176 cases, by Dukes’ stage.
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Figure 2 Five-year survival, 5176 cases, by number of nodes examined
by pathologist (log rank statistic and statistical significance calculated only
for those cases (n¼3592) where number of nodes examined is known).
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Figure 3 Five-year survival, 403 cases staged as Dukes’ A, by number of
nodes identified.
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Figure 4 Five-year survival, 1458 cases staged as Dukes’ B, by number of
nodes identified.
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sTable 2 shows results of Cox regression analysis for the multi-
variable model. Age was categorised since there was evidence that
the effect of age was not linear. The survival advantage noted for
greater number of nodes noted persists when Cox regression is
used to control for confounders. The Hazard Ratio for the 5–10
node group compared to the 0–4 node group is 0.88 (95% CI
0.80–0.98, P¼0.018) and that for the 410 group compared to the
0–4 group is 0.78 (95% CI 0.68–0.89, Po0.001), indicating
significantly reduced risk of death in the 5–10 and 410 node
groups. The average number of nodes removed by surgical firm
was not a significant predictor of survival in this multivariable
model. Figure 7 shows box and whisker plots, for each surgical
firm, of the distribution of numbers of lymph nodes identified by
pathologists in tissue removed during surgery: plots are arranged
by the number of procedures undertaken by the surgeon over the
period of the study. The variation in numbers of nodes found is
greater within firms than the variation between them.
The overall pattern of greater survival with more nodes
identified persists in the sub-group where data on lymphocytic
infiltration were available, although it does not reach statistical
significance. Figure 8 shows a significant survival advantage within
this group in those with prominent rather than moderate
lymphocytic infiltration into the primary tumour (Log Rank
Statistic¼16.86: df¼1: Po0.0001). The median (interquartile
range) number of nodes in the prominent (n¼297) and mild
0 1 2 3 4 5
0.00
0.25
0.50
0.75
1.00
>10
5–10
0–4
Survival (years)
Log rank 2 = 7.94: df = 2: P=0.019  
Figure 5 Five-year survival, 953 cases staged as Dukes’ C, by number of
nodes identified.
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Figure 6 Five-year survival, 778 cases staged as Dukes’ D, by number of
nodes identified.
Table 2 Results of Cox regression analysis of survival for the adjusted
(multivariable) model
Adjusted effect
Number of
deaths in group
(% of cases in group) Hazard ratio 95% CI
Age
o65 418 (43) 1
65–74 643 (53) 1.37 1.21–1.55
75–85 663 (61) 1.80 1.58–2.05
85+ 220 (70) 2.27 1.91–2.69
Number of lymph nodes
0–4 659 (60) 1
5–10 921 (54) 0.88 0.80–0.98
410 364 (47) 0.78 0.68–0.89
Dukes’ stage
A 105 (26) 1
B 588 (40) 1.65 1.34–2.03
C 593 (62) 3.25 2.64–4.01
D 658 (85) 7.31 5.92–9.02
Site
Left colon 709 (52) 1
Right colon 674 (57) 1.06 0.95–1.18
Rectum 561 (53) 1.09 0.98–1.22
Post-operative chemotherapy
No 1757 (54) 1
Yes 187 (60) 0.97 0.83–1.14
Histological subtype
Other 217 (59) 1
AdenoCa 1727 (54) 0.84 0.72–0.97
Average number of nodes removed by surgical firm
0–7.15 979 (52) 1
7.23–16 965 (56) 0.97 0.89–1.07
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Figure 7 Box and whisker plots, for each surgical firm, showing the
distribution of numbers of lymph nodes identified by pathologists in tissue
removed during surgery, arranged by the number of procedures under-
taken by the surgeon over the period of the study. For the sake of visual
clarity outliers and extremes are not shown. Note that the plots are
arranged in order of the average (mean) number of nodes removed by
firms, but the scale is not linear.
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s(n¼593) lymphocytic infiltration groups is eight (5–11) and seven
(4–7) respectively: this difference is significant (Mann–Whitney U
statistic 79252.5; P¼0.015).
Table 3 shows the distribution of numbers of nodes between the
two lymphocytic infiltration groups: the ‘prominent infiltration’
group contains no cases where no nodes were found at
pathological examination, and in only 23.3% of cases were fewer
than five nodes found at examination. By contrast, fewer than five
nodes were found in 32.5% of the ‘mild infiltration’ group.
DISCUSSION
The American humorist Will Rogers once joked that the move of
many residents of Oklahoma to California was increasing the
average IQ in both places. An analogous explanation for the
apparent linkage between extent of pathological examination and
cancer survival was first proposed by Feinstein in 1985, and named
‘stage migration’; the argument is that in a centre where
pathologists make a greater effort to identify lymph nodes it is
more likely that patients with nodal involvement will be staged
accurately as being in stage C (Feinstein et al, 1985; Poller, 2000).
This would have the effect of apparently improving survival in
patients in stage B by excluding patients with a worse prognosis. At
the same time, these patients might improve survival amongst
Stage C patients, as they are likely to be better prognostically than
those graded as Dukes’ C by pathologists who do not make such an
effort. It can be expected, therefore, that the number of lymph
nodes identified by a pathologist following surgery for colorectal
cancer predicts long-term survival in both stage B and stage C
disease. In our study, however, the pattern is seen in the
population as a whole, and is similar within each individual stage
group, although significance is reached only in Dukes’ B and
Dukes’ C groups. Several alternative explanations for these
findings need to be considered.
First, stage migration. This is the conclusion reached by most
authors who have published on the subject, and is a perfectly
acceptable explanation for the relationship observed between
number of nodes removed and prognosis in Dukes’ B and C
disease seen in this study. However, had IQ been measured in the
combined population of Oklahoma and California this pheno-
menon could not have been observed, nor become the subject of a
joke: there would simply have been no change in IQ associated
with population movement. Our study shows a significant survival
advantage related to number of nodes removed across the whole
study population, without division into stages. This cannot be
explained by stage migration alone, as any artefact brought about
by incorrect staging is eliminated when all stages are considered
together. Stage migration may still contribute to the relationship
seen within individual stages, however, except for one: it is
interesting to note that a relationship between number of nodes
removed and survival, similar in both direction and magnitude to
that seen in Stage B and C patients, is also seen in Stage D patients,
although this does not attain statistical significance (P¼0.068).
Type II statistical error is the most likely explanation for this, based
on the smaller group size. However, as node status misclassification
cannot influence whether a patient is placed in stage D, patients
being classified thus on the basis of presence of distant metastases,
this finding supports, albeit softly, our contention that stage
migration cannot be the sole explanation for our findings.
If the artefactual explanation offered by stage migration cannot
completely explain our results, we must consider other means by
which the number of nodes identified by the pathologist could
impact upon survival. Several suggest themselves. First, taking out
more lymph nodes may reflect superior technical ability on behalf
of the surgeon. Second, the identification of lymph nodes
containing tumour may change the management of the patient
in some way (e.g. by the giving of adjuvant chemotherapy). Third,
it may be that the number of lymph nodes present may relate to
other factors affecting survival, principally geographical site of the
tumour. Last, lymph node enlargement leading to easier harvesting
may in itself be a prognostic factor in the patient’s outcome.
The first explanation is the most intuitive: surgeons removing a
specimen containing more lymph nodes are performing a more
radical and technically accomplished operation than those who
have a small harvest of lymph nodes, and the impact of the surgeon
on outcome in patients having colorectal surgery is well reported
(Meagher, 1999). The traditional and radical approach to colon
cancer is to remove the tumour with all its associated nodes up to
and including the level of the principal arterial supply, and it is self
evident that the more of the mesentery that is removed along with
the tumour the more nodes there will be that are available for
pathological harvest. However, most surgeons will aim to carry out
the same operation on each similar patient they treat, whereas it is
apparent from our data that the difference in numbers of nodes
removed within a surgical firm (i.e. between patients) is greater
than that between surgical firms. Mathematically, the average
number of nodes taken out by a surgical firm is not a significant
predictor of survival in this multi-variable model, whereas the
advantage conferred by the individual number of nodes removed
remains.
Another explanation concerns changes in management brought
about by the finding of involved lymph nodes. However,
participants in this study were recruited between 1991 and 1994.
During that period only a minority of patients in the UK, even in
Dukes stage C, had postoperative chemotherapy in the hospitals
concerned, and receipt of chemotherapy did not contribute
significantly to our regression model.
It is possible that number of nodes is associated with site
of tumour, itself a prognostic variable in colorectal cancer.
Survival (years)
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Figure 8 Five-year survival, 890 cases with data on degree of
lymphocyte infiltration into primary tumour, by degree of lymphocytic
infiltration (prominent, n¼297: mild, n¼593).
Table 3 Distribution of numbers (percentages) of cases by number of
lymph nodes identified in 890 cases with data on degree of lymphocyte
infiltration into primary tumour, and by degree of lymphocytic infiltration
Number of nodes
0 1 2 3 4 5–10 11+ Total
Prominent
infiltration
0 (0)10 (3.3)13 (4.3)17 (5.7) 30 (10) 151 (51) 76 (25) 297
Mild infiltration6 (1)30 (5) 34 (5.7)68 (11.4)56 (9.4)250 (42)149 (25) 593
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presentation. Also, rectal tumours are thought by many to have a
poorer prognosis (stage for stage) than colonic cancers, and some
authors have reported that there are fewer nodes found around the
rectum than around other segments of the colon (Maurel et al,
1998). Again, however, site of tumour did not contribute
significantly to our regression model.
Another possible explanation is based upon the observation that
reactive lymph node enlargement is itself a prognostic factor in
colorectal carcinoma (Pihl et al, 1980). The number of nodes found
within a specimen relies on two principal factors: first, the amount
of tissue, particularly mesenteric, taken out by the surgeon and,
second, the number of nodes that the pathologist is able to find in
the specimen. The first of these we have already found not to be a
significant predictor of survival in this model. The real explanation
for our findings may relate to how easy it is for the pathologist to
locate lymph nodes. Tiny lymph nodes in a fatty mesentery can be
extraordinarily difficult to locate, whereas large nodes in a thin
mesentery are comparatively easy to find. Lymph nodes enlarged
because of malignancy are more easily found but, in addition, it is
probable that uninvolved nodes enlarged because of reactive
change are also more easily found. It is known that immune
response to colorectal cancer affects survival: patients who have
tumours with a pronounced lymphocytic infiltrate have a good
prognosis compared with those who have no such infiltration
(Jass, 1986; Fernandez-Acenero et al, 2000; Murphy et al, 2000;
Canna et al, 2005). We have shown here that the number of lymph
nodes found by the pathologist is increased in those with
prominent lymphocytic infiltration of the primary tumour. It
may be, therefore, that the number of lymph nodes found is a
function of their reactive enlargement. Recent UK guidelines
suggesting that a minimum of 12 nodes be examined may be easier
to implement in some patients than in others, therefore (National
Institute for Clinical Excellence, 2004). It may also be time to
consider whether to include an assessment of the degree of
lymphocytic infiltration into the primary tumour as part of the
minimum data set.
In conclusion, we have demonstrated that the number of lymph
nodes harvested in patients with curable colorectal cancer
correlates with a better survival, and also with immune reaction
to tumour. It is likely that some of the survival advantage noted in
this study is due to stage migration, and we do not doubt the value
of impeccable surgical technique and pathological examination.
However, stage migration alone cannot explain our results, and
it may be that biological predetermination is a key factor in
differences in patient survival from colorectal cancer (Macdonald,
1951; Jass, 1999).
ACKNOWLEDGEMENTS
The Wessex Colorectal Cancer Audit was funded by local district
health authorities, by the Wessex Regional Medical Audit Fund, by
the Wessex Cancer Trust, and by the UK Department of Health.
We thank them all. The views expressed, however, are those of the
authors alone. We thank all of those whose efforts resulted in the
successful completion of data collection for this study. We thank
Dr Bianca de Stavola, of the London School of Hygiene and
Tropical Medicine, for her help with some of the statistical issues.
Contributors
SG, JP RT and JS agreed overall design of the study. DB and HJ
prepared the data set and gave detailed advice on data. CdB gave
advice on pathology of colorectal cancer. SG, MM and JP
undertook the analysis. All authors contributed to the writing of
the paper, SG and JP wrote the final version with assistance from
all the authors.
Ethics
This study was conducted using a precollected anonymised data
set and ethics approval was not required.
REFERENCES
Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF,
McArdle CS (2005) The relationship between tumour T-lymphocyte infil-
tration, the systemic inflammatory response and survival in patients under-
going curative resection for colorectal cancer. Br J Cancer 92: 651–654
Caplin S, Cerottini JP, Bosman FT, Constanda MT, Givel JC (1998) For
patients with Dukes’ B (TNM Stage II) colorectal carcinoma, examination of
six or fewer lymph nodes is related to poor prognosis. Cancer 83: 666–672
Cserni G, Vinh-Hung V, Burzykowski T (2002) Is there a minimum number
of lymph nodes that should be histologically assessed for a reliable nodal
staging of T3N0M0 colorectal carcinomas? J Surg Oncol 81: 63–69
Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon.
Stage migration and new diagnostic techniques as a source of misleading
statistics for survival in cancer. N Engl J Med 312: 1604–1608
Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A (2000)
Prognostic influence of tumor-associated eosinophilic infiltrate in
colorectal carcinoma. Cancer 88: 1544–1548
Goldstein NS (2002) Lymph node recoveries from 2427 pT3 colorectal
resection specimens spanning 45 years: recommendations for a
minimum number of recovered lymph nodes based on predictive
probabilities. Am J Surg Pathol 26: 179–189
Jass JR (1986) Lymphocytic infiltration and survival in rectal cancer. J Clin
Pathol 39: 585–589
Jass JR (1999) Towards a molecular classification of colorectal cancer. Int J
Colorectal Dis 14: 194–200
Jestin P, Pahlman L, Glimelius B, Gunnarsson U (2005) Cancer staging and
survival in colon cancer is dependent on the quality of the pathologists’
specimen examination. Eur J Cancer 41: 2071–2078
Macdonald I (1951) Biological predeterminism in human cancer. Surg
Gynecol Obstet 92: 443–452
Maurel J, Launoy G, Grosclaude P, Gignoux M, Arveux P, Mathieu-Daude
H, Raverdy N, Faivre J (1998) Lymph node harvest reporting in patients
with carcinoma of the large bowel: a French population-based study.
Cancer 82: 1482–1486
Meagher AP (1999) Colorectal cancer: is the surgeon a prognostic factor? A
systematic review. Med J Aust 171: 308–310
Michiels C, Boutron MC, Chatelain N, Quipourt V, Roy P, Faivre J (1994)
Prognostic factors in colorectal adenocarcinoma of Dukes stage B. Study
of a series of population. Gastroenterol Clin Biol 18: 456–461
Murphy J, O’Sullivan GC, Lee G, Madden M, Shanahan F, Collins JK, Talbot
IC (2000) The inflammatory response within Dukes’ B colorectal cancers:
implications for progression of micrometastases and patient survival.
Am J Gastroenterol 95: 3607–3614
National Institute for Clinical Excellence (2004) Guidance on Cancer
Services: Improving Outcomes in Colorectal Cancers: Manual Update.
London: National Institute for Clinical Excellence
Pihl E, Nairn RC, Milne BJ, Cuthbertson AM, Hughes ES, Rollo A (1980)
Lymphoid hyperplasia: a major prognostic feature in 519 cases of
colorectal carcinoma. Am J Pathol 100: 469–480
Poller DN (2000) Method of specimen fixation and pathological dissection
of colorectal cancer influences retrieval of lymph nodes and tumour
nodal stage. Eur J Surg Oncol 26: 758–762
Prandi M, Lionetto R, Bini A, Francioni G, Accarpio G, Anfossi A,
Ballario E, Becchi G, Bonilauri S, Carobbi A, Cavaliere P, Garcea D,
Giuliani L, Morziani E, Mosca F, Mussa A, Pasqualini M, Poddie D,
Tonetti F, Zardo L, Rosso R (2002) Prognostic evaluation of stage B
colon cancer patients is improved by an adequate lymphadenectomy:
results of a secondary analysis of a large scale adjuvant trial. Ann Surg
235: 458–463
Prospective observational study
S George et al
846
British Journal of Cancer (2006) 95(7), 841–847 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sRothman K (1986) Multivariate analysis. In Modern Epidemiology Rothman
K (ed) Boston: Little, Brown & Co
Schottenfeld D, Winawer SJ (1996) Cancers of the large intestine. In Cancer
Epidemiology and Prevention Schottenfeld D, Fraumeni JE (eds) pp 813–
840. New York: Oxford University Press
Swanson RS, Compton CC, Stewart AK, Bland KI (2003) The prognosis of
T3N0 colon cancer is dependent on the number of lymph nodes
examined. Ann Surg Oncol 10: 65–71
Tepper JE, O’Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson III
AB, Cummings B, Gunderson L, Macdonald JS, Mayer RJ (2001) Impact
of number of nodes retrieved on outcome in patients with rectal cancer.
J Clin Oncol 19: 157–163
Williams NS, Northover JMA, Arnott SJ, Jass JR (1995) Colorectal
tumours. In Oxford Textbook of Oncology Peckham M,
Pinedo HM, Veronisi U (eds) pp 1133–1168. Oxford: Oxford University
Press
Prospective observational study
S George et al
847
British Journal of Cancer (2006) 95(7), 841–847 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s